跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
AMITIZA
Authorized
STANDARD
AMITIZA
Sucampo Pharma Americas LLC
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4a5e7c27d00afe47
Company
Sucampo Pharma Americas LLC
Type
Standard
Approval Details
Approval Id
4a5e7c27d00afe47
Drug Approval Canada Name
AMITIZA
Product Name
AMITIZA
Status
Cancelled Pre Market
Status Date
2020-12-17
Din
02447363
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
56:92.00
Atc Original
A06AX03 LUBIPROSTONE
Atc Name
a 06 ax 03
Aig Number
0157490001
Company Name
Sucampo Pharma Americas LLC
Company Address
206-1425 Us Highway, Bedminster, New Jersey, United States, 07921
Company Detail Path
/organization/sucampo-pharma-americas-llc-united-states
Company Information
Pharmaceutical Company Name
Sucampo Pharma Americas LLC
Country Name
United States
Province Name
马里兰州
Active Ingredients
LUBIPROSTONE
24 MCG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4a5e7c27d00afe47
Type
Standard
Back to Health Canada Approvals
AMITIZA - Health Canada Drug Approval Details